Enobosarm
QUALITY
Veru Inc · Phase 2 · Completed · Enrollment 168
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily | Obesity or overweight | 3 mg | 1 | n/r | n/r |
| Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily | Obesity or overweight | 6 mg | 1 | n/r | n/r |
| GLP-1 receptor agonist and Placebo QD by mouth (PG) daily | Obesity or overweight | n/r | 1 | n/r | n/r |